ZGNX Brean initiation report (partial) Future Looks Brighter for Zogenix, Initiate with BUY and $2.50 TP Investment Summary We are initiating coverage of Z, Inc. with a BUY rating and a $2.50 TP. Zogenix has commercialized a controversial product, Z ER, and we believe the market under-appreciates the medical value this product brings to patients and pain-treating specialists. Despite the heated debate and intense negative coverage from the media, we are impressed that the product is performing well during early launch days.
لا يُقصد بالمعلومات والمنشورات أن تكون، أو تشكل، أي نصيحة مالية أو استثمارية أو تجارية أو أنواع أخرى من النصائح أو التوصيات المقدمة أو المعتمدة من TradingView. اقرأ المزيد في شروط الاستخدام.